American Public Education (NasdaqGS:APEI) Q4 2025 Earnings call March 12, 2026 05:00 PM ET Company ParticipantsAlex Paris - President and Senior Managing DirectorAngela Selden - President and CEOEdward Codispoti - EVP and CFOGary Janson - SVP of Growth, Financial Planning and AnalysisShannon Devine - Investor RelationsConference Call ParticipantsEric Martinuzzi - Senior Research AnalystGriffin Boss - Equity Research AnalystJasper Bibb - VP and Senior Equity AnalystLuke Horton - VP and Senior Research Analys ...

Financial Data and Key Metrics Changes - The company ended 2025 with $245.8 million in cash and investments and no debt on its balance sheet [16][41] - Revenue for Q4 2025 was $21.8 million, with a full-year revenue of $55.2 million [43] - R&D expenses for Q4 2025 were $29.7 million, totaling $117.3 million for the full year [43] - G&A expenses for Q4 2025 were $11.2 million, with a full-year total of $68.7 million [43] - The net loss for Q4 2025 was $36.1 million, or $1.78 per share, while the full-year net loss was $164.1 million, or $9.73 per share [43][44] Business Line Data and Key Metrics Changes - The company is focusing on advancing its immunology and inflammation pipeline, particularly the Treg biologic, rezpegaldesleukin [6][7] - Positive results were achieved in phase 2b studies for atopic dermatitis and alopecia areata, validating the Treg mechanism [8][10] - The atopic dermatitis market is projected to grow to approximately $35 billion by the mid-2030s, with significant unmet needs in treatment [11][12] Market Data and Key Metrics Changes - In the U.S., over 15 million people suffer from moderate to severe atopic dermatitis, with only 10%-15% currently receiving biologic treatments [10] - Approximately 50% of patients fail to respond or lose treatment effect over time with current IL-13-based therapies, indicating a significant opportunity for REZPEG [11][12] Company Strategy and Development Direction - The company plans to initiate phase 3 studies for REZPEG in June 2026, with a goal to submit a BLA in 2029 [15][16] - The competitive landscape for late-stage novel mechanisms of action (MOAs) has narrowed, positioning REZPEG favorably [12] - The company aims to leverage its differentiated efficacy and safety profile to capture market share in the atopic dermatitis and alopecia areata markets [12][13] Management's Comments on Operating Environment and Future Outlook - Management highlighted the successful outcomes of phase 2 studies and the potential for REZPEG to provide complete disease clearance over time [9][10] - The company expressed confidence in its strong balance sheet, allowing for rapid advancement into phase 3 studies [16][41] - Management noted the importance of achieving a differentiated safety profile compared to existing treatments, particularly JAK inhibitors [13][56] Other Important Information - The company raised approximately $476 million in additional net cash through a public offering and ATM exercises [16][41] - The phase 3 program for REZPEG will evaluate both biologic-naive and treatment-experienced patients [27][61] Q&A Session Summary Question: What type of new data can be expected from the AAD conference presentation? - The upcoming presentation will showcase additional effects of treatment with REZPEG and potential for more patients to achieve SALT 20 responses [49][51] Question: Will ACQ-5 data be included in the phase 3 program? - ACQ-5 will be included in the phase 3 program, and efforts will be made to include it in the label [61] Question: What is the formulation or device for REZPEG being considered? - REZPEG will be launched in an auto-injector device, with weight-banded dosing for ease of administration [71] Question: How many patients completed the extension phase of the alopecia study? - There were 23 patients ongoing in the 16-week extension, and all treatment stops for all patients at either week 36 or week 52 [114] Question: How does REZPEG differentiate from other approaches in type 1 diabetes? - REZPEG offers an outpatient dosing regimen without the need for routine monitoring, contrasting with the IV infusion required for Tzield [108][109]

PagerDuty (NYSE:PD) Q4 2026 Earnings call March 12, 2026 05:00 PM ET Company ParticipantsHoward Wilson - CFOJennifer Tejada - Chairperson and CEOKingsley Crane - Managing Director of Equity ResearchMiller Jump - Equity Research AssociateSanjit Singh - Executive DirectorVijay Homan - Equity Research AssociateConference Call ParticipantsGeorge McGrean - AnalystOperatorGood afternoon, and thank you for joining us to discuss PagerDuty's fourth quarter and full year fiscal 2026 results. With me on today's call a ...

Financial Data and Key Metrics Changes - Consolidated revenue for 2025 grew to $135 million, reflecting a 23.4% increase year-over-year, with Q4 revenue up 30.1% to $38.6 million [4][15] - Consolidated adjusted EBITDA for the year was $7.8 million, with Q4 adjusted EBITDA at $2.7 million [4][15] - Consolidated net loss for the year was $10.3 million, with a quarterly net loss of $1.6 million [15] Business Line Data and Key Metrics Changes - KSX segment revenue increased by 63.6% to $20.3 million for Q4 and was up 58.5% to $64.2 million for the year [15] - KSX adjusted EBITDA rose by 28.6% to $2.5 million for Q4 and was up 40.8% to $9.5 million for the year [15] - Extended warranty revenue increased by 6.1% to $18.3 million for Q4 and was up 2.8% to $70.8 million for the year [16] Market Data and Key Metrics Changes - Extended warranty cash sales grew by 11% for Q4 and 9% for the year, with claims costs moderating to a 4.4% increase for the year compared to 6.3% in the prior year [16][17] Company Strategy and Development Direction - The company aims for double-digit organic growth across both KSX and extended warranty segments in 2026, alongside a target of 3-5 acquisitions [5][10] - The strategy focuses on acquiring companies with recurring revenues and strong growth tailwinds, supported by a decentralized management model [3][7] - The company has completed six acquisitions in 2025 and launched a new skilled trades platform, positioning itself for accelerated growth [4][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong organic growth due to the characteristics of the businesses owned and the talent of operator leaders [7][10] - The focus for 2026 includes enhancing value through cross-selling and continued organic growth, with a robust acquisition pipeline [11][13] - Management highlighted the importance of creating a solid foundation for new businesses before pursuing aggressive growth [42] Other Important Information - The company had $8.3 million in cash and cash equivalents at year-end 2025, up from $5.5 million at the end of 2024, while total debt increased to $70.7 million [17][18] - The portfolio LTM adjusted EBITDA was reported at $22 million-$23 million, reflecting the trailing twelve-month performance of the operating businesses [4][19] Q&A Session Summary Question: Update on Digital Diagnostics - Management noted that Digital Diagnostics grew in the high single digits and emphasized the focus on building a solid foundation for future growth [30][42] Question: Acquisition Pipeline - Management confirmed a dual-track acquisition pipeline with strong deal flow and disciplined underwriting criteria [50] Question: Adjustments from Consolidated Adjusted EBITDA to Portfolio LTM EBITDA - The adjustments include pro forma results, differences in modified cash EBITDA for warranty companies, and corporate expenses [52][54] Question: Margin Expansion for Image Solutions and Skilled Trades - Management indicated that investments made in 2025 have set the stage for improved profitability and growth in 2026 [55][56] Question: Double-Digit Growth Drivers - Management expects universal growth across all businesses, driven by revenue growth, efficiency gains, and pricing strategies [57] Question: Tuck-In Acquisitions vs. New Platforms - Management anticipates targeting at least one to two new platform investments, with the remainder being tuck-in acquisitions [58]

Financial Data and Key Metrics Changes - Adobe achieved revenue of $6.4 billion in Q1 FY 2026, representing an 11% year-over-year growth [11][32] - GAAP earnings per share (EPS) for the quarter was $4.60, and non-GAAP EPS was $6.06, reflecting 11% and 19% year-over-year growth, respectively [11][32] - Total Adobe ending Annual Recurring Revenue (ARR) reached $26.06 billion, growing 10.9% year-over-year [32] - Cash flows from operations in the quarter were a record $2.96 billion, with ending cash and short-term investments at $6.89 billion [33] Business Line Data and Key Metrics Changes - Subscription revenue for business professionals and consumers was $1.78 billion, increasing 15% year-over-year [32][33] - Creative and marketing professionals' subscription revenue was $4.39 billion, growing 11% year-over-year [17][32] - Monthly Active Users (MAU) for Acrobat and Express grew approximately 20% year-over-year, with Creative Premium MAU crossing 80 million, growing 50% year-over-year [35][14] Market Data and Key Metrics Changes - Adobe's global enterprise offerings saw over 30% year-over-year growth in Adobe Experience Platform (AEP) and applications [10] - The company reported strong momentum in AI-first applications, with ARR from these applications more than tripling year-over-year [11][36] - Firefly subscription and credit pack ending ARR grew 75% quarter-over-quarter, indicating strong adoption in content automation [18][36] Company Strategy and Development Direction - Adobe is focusing on an AI-driven business model, targeting business professionals and consumers through AI-infused product offerings [7][11] - The company aims to empower everyone to create, leveraging its leadership in creativity and productivity tools [6][12] - Adobe is expanding its product portfolio with new offerings like Adobe Acrobat Studio and Adobe Firefly, which are designed to enhance user experience and drive growth [8][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in Adobe's ability to capitalize on AI opportunities, emphasizing the importance of customer-centric strategies and innovation [11][39] - The company anticipates continued growth in MAU and usage of AI functionalities, which are expected to drive future revenue [37][38] - Management acknowledged a decline in traditional stock business but remains focused on providing customers with choices between stock and generative AI offerings [37][39] Other Important Information - Adobe's acquisition of Semrush is expected to enhance its offerings in digital marketing and brand visibility [28] - The company serves 99 of the Fortune 100 and is a trusted partner for enterprises in customer experience management [23][24] Q&A Session Summary Question: Insights on RPO and Revenue Visibility - Dan Durn noted that the company is pleased with the momentum in RPO and does not foresee significant changes in revenue visibility [44][45] Question: CEO Transition Expectations - Shantanu Narayen highlighted the importance of product innovation and the board's role in selecting the next CEO, indicating the process may take a few months [49][80] Question: Generative Credit Consumption Trends - David Wadhwani explained that the increase in generative credit consumption is due to higher user engagement and integration of AI into existing workflows [53][54] Question: Revenue Acceleration Factors - Shantanu Narayen discussed the impact of new user adoption and the strength of enterprise solutions on revenue growth, clarifying the stock business's relatively small impact [59][63] Question: Future Growth Initiatives - Shantanu Narayen emphasized the focus on creativity and productivity as key growth drivers, with expectations for continued strong performance in AI-driven offerings [70][75]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $69.3 million, exceeding the high end of guidance, driven by higher variable revenue [21] - Adjusted EBITDA for Q4 was $10.8 million, also above the high end of guidance, attributed to cost restructuring and disciplined operational execution [21] - Recurring revenue constituted 89% of total revenue, with a decline in professional services revenue by 36% year-over-year [21][22] - Average revenue per customer increased by 9% year-over-year to $680,000 [22] - Cash on the balance sheet at the end of Q4 was $95 million [22] Business Line Data and Key Metrics Changes - Revenue from hosted services was $51 million, down 15% year-over-year [21] - Professional services revenue was $8.3 million, reflecting a significant decline [21] - The launch of Syntrix is expected to drive upsell opportunities and improve retention capabilities [45] Market Data and Key Metrics Changes - The company signed 40 deals in Q4, including 4 new logos and 36 expansions, indicating a slight increase in total deal value [18] - Strong adoption of the platform was noted in regulated industries such as banking, telecommunications, and airlines [19] - Over 20% of all conversations in Q4 leveraged Generative AI tools, indicating deeper AI adoption [8] Company Strategy and Development Direction - The company is focused on three primary areas: customer growth and retention, innovation in the Conversational Cloud platform, and expanding technology partnerships [4] - Syntrix is positioned as a comprehensive assurance layer for AI deployments, addressing market gaps in trust and compliance [6][7] - The partnership with Google Cloud is expected to simplify procurement and enhance customer retention, with a material fraction of revenue anticipated to flow through this channel by the end of 2026 [10][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving positive net new ARR in the second half of 2026, despite expected revenue declines throughout the year [16][23] - The company aims to transition from stabilization to targeted execution, leveraging high-efficiency channels for customer retention and future growth [25] - The focus remains on disciplined execution of strategic priorities, including product innovation and strengthening the partner network [25] Other Important Information - The company expects revenue for the full year 2026 to range from $195 million to $207 million, with approximately 92% expected to be recurring [23] - Adjusted EBITDA for 2026 is projected to range from a loss of $4 million to a gain of $7 million [24] Q&A Session Summary Question: Can you walk us through the decrease in total OpEx for Q4? - The decrease was primarily due to a large restructuring executed in the prior quarter, with some one-time items but mainly structural changes [29] Question: How do you expect net new ARR to grow while revenue declines? - Historical customer losses will offset the positive revenue from net new ARR, leading to sequential revenue declines [31] Question: Can you expand on the demand for Syntrix and its development? - Demand initially focused on simulation capabilities, evolving into a broader solution addressing compliance and governance challenges in AI deployments [36][38] Question: What is the pricing model for Syntrix? - The pricing model is conversation-based, reflecting consumption rather than seat-based, and is expected to drive upsell opportunities [43][45] Question: How does Google Cloud Marketplace impact your sales strategy? - It serves as a retention lever, simplifying procurement and potentially increasing renewals and new opportunities through aligned incentives [47][51]

Financial Data and Key Metrics Changes - For the full year 2025, the company reported revenue of $175 million, a decline of approximately 5% from $185 million in 2024, with fourth-quarter revenue at $43 million, down 10% year-over-year [4][14] - Adjusted EBITDA for the full year was $40 million, compared to $43 million in 2024, reflecting the company's cost control efforts despite revenue decline [17] - The company ended the year with $62 million in cash, marking an almost 20% increase from the end of 2024 [4] Business Line Data and Key Metrics Changes - Average paying clients in the fourth quarter were 5,120, down approximately 2% year-over-year, while for the full year, average paying clients were 5,190, up 2% compared to 2024 [14][15] - Average revenue per paying client for both the fourth quarter and the full year was approximately $2,800, down from prior year levels due to lower spending from existing clients [15] Market Data and Key Metrics Changes - The company experienced severe pricing compression and competition from illicit markets, particularly affecting mature markets like California and Michigan, where total retail sales and average retail prices declined year-over-year [13] - Encouraging growth was noted in newer markets such as New York and Ohio, where client penetration was prioritized, although this growth did not offset pressures in mature markets [14] Company Strategy and Development Direction - The company remains focused on enhancing product offerings and deepening relationships with large California-based clients and MSO partners, while also improving marketplace experience [8] - Investments are planned across teams and technology to build for the future, despite the challenges posed by industry consolidation and regulatory limitations [8][10] Management's Comments on Operating Environment and Future Outlook - Management highlighted that many industry dynamics affecting clients in 2025 are expected to persist into 2026, with first-quarter revenue anticipated to decline sequentially by mid- to high-single digits from the fourth quarter [17] - The company is committed to preserving financial flexibility and disciplined capital allocation while assessing future opportunities [18] Other Important Information - The company recorded a non-cash asset impairment charge of approximately $7.8 million in the fourth quarter, primarily related to goodwill [16] - Management expressed optimism about the potential benefits of cannabis rescheduling, although it will not immediately change the company's operational capabilities [10][11] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session. The call concluded without further inquiries [19]

Financial Data and Key Metrics Changes - In Q4 2025, EverCommerce generated revenue of $151.2 million, representing a 5.2% year-over-year growth [6][20] - Adjusted EBITDA for the quarter was $44.2 million, with a margin of 29.2%, reflecting operational discipline and efficiency improvements [21][22] - Pro forma revenue for the last 12 months was $591.7 million, indicating a 6.4% year-over-year growth [8][20] Business Line Data and Key Metrics Changes - EverHealth and EverPro verticals were highlighted as key areas of focus, with both verticals contributing approximately 95% of consolidated revenue [7][8] - Multi-solution customers grew by 26% year-over-year, with 286,000 customers enabled for more than one solution [16] - The top six payment solutions saw a 17.4% year-over-year growth in total payment volume (TPV) [17] Market Data and Key Metrics Changes - The annualized total payments volume (TPV) expanded to $13 billion, showcasing significant market engagement [8] - The company reported a net revenue retention rate of 96%, with multi-solution customers generating NRR above 100% [17] Company Strategy and Development Direction - The company is focused on embedding AI across its platforms to enhance customer experiences and operational efficiency [63] - Investments in AI-driven features and workflows are expected to drive durable growth and improve financial performance [26][63] - The acquisition of ZyraTalk is seen as a foundational step towards enhancing AI capabilities within the company's offerings [5][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects for 2026, driven by AI investments and improved customer engagement [36][39] - The company anticipates continued operational leverage and efficiency gains through AI integration [15][63] - Seasonal performance is expected to influence revenue growth, with stronger performance anticipated in Q2 and Q3 [26][58] Other Important Information - The company repurchased approximately 2.5 million shares for $24.8 million during Q4 2025, with a remaining repurchase authorization of $47.7 million [25] - The leadership update included Matt Feierstein taking on the role of CEO for EverPro, emphasizing continuity in strategy execution [18] Q&A Session Summary Question: Customer appetite for AI solutions - Management noted strong uptake in AI functionalities across EverPro, with positive early sales from ZyraTalk integrations [30][32] Question: 2026 growth outlook assumptions - The company highlighted investments in AI and customer engagement as key drivers for growth, expecting re-acceleration throughout the year [36][39] Question: Payments revenue decline explanation - Management clarified that the decline in non-top six payment solutions was not related to the MarTech divestiture, focusing instead on the growth of the top six solutions [42][44] Question: Competitive advantages in the AI landscape - Management emphasized the importance of deep niche vertical expertise and a large customer base as competitive advantages in the evolving AI market [45][48]

Financial Data and Key Metrics Changes - The company ended 2025 with $245.8 million in cash and investments and no debt on its balance sheet [16][41] - Revenue for Q4 2025 was $21.8 million, with a full-year revenue of $55.2 million [43] - R&D expenses for Q4 2025 were $29.7 million, totaling $117.3 million for the full year [43] - The net loss for Q4 2025 was $36.1 million, resulting in a basic and diluted net loss per share of $1.78, while the full-year net loss was $164.1 million, or $9.73 per share [43][44] Business Line Data and Key Metrics Changes - The company is focusing on advancing its immunology and inflammation pipeline programs, particularly the Treg biologic, rezpegaldesleukin (REZPEG) [6][7] - Positive results were achieved in phase two studies for REZPEG in atopic dermatitis and alopecia areata, validating its novel regulatory T-cell mechanism [8][10] - The atopic dermatitis market is projected to grow to approximately $35 billion by the mid-2030s, with only 10%-15% of patients currently receiving biologic treatments [11][12] Market Data and Key Metrics Changes - There are over 15 million people in the U.S. with moderate to severe atopic dermatitis, presenting a significant market opportunity [10] - The competitive landscape for late-stage novel mechanisms of action (MOAs) has narrowed, positioning REZPEG favorably [12] - The company anticipates that the atopic dermatitis market will see increased adoption of biologics, with a significant opportunity for REZPEG due to its differentiated efficacy and safety profile [11][12] Company Strategy and Development Direction - The company plans to randomize the first patient in phase three studies for atopic dermatitis in June 2026, with a goal to submit a Biologics License Application (BLA) in 2029 [15][16] - REZPEG is positioned as a potential first-in-class biologic in alopecia areata, with plans to advance into phase three following positive phase two results [29][32] - The company is exploring additional indications for REZPEG, including skin and autoimmune diseases, food allergies, and asthma [36][107] Management's Comments on Operating Environment and Future Outlook - Management highlighted the successful outcomes from phase two studies as a pivotal moment for the company, indicating strong potential for REZPEG in treating inflammatory diseases [8][10] - The management expressed confidence in the differentiated safety profile of REZPEG compared to existing treatments, particularly JAK inhibitors, which have significant safety concerns [13][56] - The company is optimistic about the future growth of the atopic dermatitis market and the potential for REZPEG to capture a significant share due to its unique mechanism of action [11][12][125] Other Important Information - The company raised approximately $476 million in additional net cash through a public offering and an ATM facility, strengthening its balance sheet for future investments [16][41] - The company has established a strong safety database for REZPEG, with over 1,000 patients treated to date [26][41] Q&A Session Summary Question: What type of new data could be seen at the AAD conference regarding the alopecia areata study? - Management indicated that the upcoming presentation will showcase additional effects of treatment with REZPEG and the potential for more patients to achieve SALT 20 responses [48][51] Question: Will the ACQ-5 data be included in the phase three program for atopic dermatitis? - Management confirmed that ACQ-5 will be included in the phase three program, with efforts to include it in the label [61] Question: What is the formulation or device for REZPEG being considered for commercial launch? - The plan is to launch REZPEG in an auto-injector device, with weight-banded dosing for ease of administration [71][72] Question: How does REZPEG differentiate from other approaches in type one diabetes? - Management highlighted that REZPEG offers an outpatient dosing regimen without the need for routine monitoring, contrasting with the more complex administration of existing therapies [108][109]

Financial Data and Key Metrics Changes - In Q4 2025, the company reported revenue of $6.2 million, exceeding guidance, compared to $6.7 million in Q4 2024, reflecting a decrease due to the exit of lower-margin business [7][11] - GAAP gross margin improved to 18.1% from -14.9% in Q4 2024, while non-GAAP gross margin rose to 25.6% from -5.2% in the same period [7][11] - For fiscal year 2025, revenue was $21.5 million, down $5.1 million from the previous year, with GAAP gross margin at 6.1% and non-GAAP gross margin at 14.3%, both showing significant improvement from fiscal year 2024 [11][12] Business Line Data and Key Metrics Changes - The transition of production from Singapore to Thailand has structurally reduced costs and improved manufacturing efficiency, contributing to margin expansion [5][18] - The company has completed its transition to a pure-play IoT company, enhancing focus on high-value IoT opportunities [18][19] Market Data and Key Metrics Changes - The company is scaling production to support IFCO's requirement for 100 million BLE smart labels per year, with ongoing opportunities to tag their full pool of over 400 million reusable containers [32][33] - The customer-driven opportunities in the pipeline are approximately 25% in healthcare, 25% in logistics, and 25% in food and beverage, with the remainder in various applications [36] Company Strategy and Development Direction - The company is focused on its Perform, Accelerate, and Transform strategy, aiming to strengthen core business, drive operational efficiency, and expand margins [3][17] - Key initiatives include the development of BLE technology, multi-component manufacturing, and strategic partnerships to enhance innovation and market positioning [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress made in 2025 and the operational foundation established for profitable growth in 2026 [17][29] - The company anticipates variability in gross margins as it scales production for the IFCO program and a new customer in Q1 2026, but expects overall margin expansion as operations stabilize [15][48] Other Important Information - The company exited Q4 2025 with $128.9 million in cash equivalents, reflecting a strong balance sheet [13][15] - The company has implemented new enterprise software systems to enhance operational efficiency and customer responsiveness [18] Q&A Session Summary Question: Insights on the IFCO opportunity and revenue potential - Management highlighted the exclusive agreement with IFCO, aiming to scale up to 100 million units per year, with a higher price point than average products, though gross margins will be below the target of 30% [32][33] Question: Breakdown of the new opportunity pipeline by end market - Approximately 25% of the current pipeline opportunities are in healthcare, logistics, and food and beverage, with the rest in various applications [36] Question: Contribution of gross margin drivers in 2026 - Management indicated that while there may be near-term variability in gross margins due to scaling for the IFCO project, they expect overall margin expansion as operations improve [48]